• On August 5, 2026, Schrödinger, Inc. announced a new agreement to deploy its Bunsen agentic AI co-scientist and related computational tools across Bristol Myers Squibb’s research organization, expanding their long-running collaboration in early-stage drug discovery.
• This move highlights how Bristol Myers Squibb is leaning further into AI-driven, physics-based modeling to potentially refine molecule selection and speed up discovery decisions within its pipeline.
• Next, we’ll examine how Bristol Myers Squibb’s deeper use of Schrödinger’s Bunsen AI platform could influence its existing investment narrative.

The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Bristol-Myers Squibb Investment Narrative Recap

Bristol Myers Squibb’s investment case rests on whether its newer therapies and pipeline can eventually counterbalance looming patent cliffs and pricing pressure. The expanded Schrödinger AI collaboration may incrementally support R&D productivity, but it does not materially change the near term focus on replacing Eliquis and Opdivo cash flows or the core risk around concentration in a few blockbuster drugs.

Against that backdrop, BMS’s latest quarterly results are an important reference point: Q2 2026 revenue rose to US$12,973 million and net income to US$3,317 million, with higher profit margins despite no additional share repurchases. These numbers frame how much room BMS has to invest in platforms like Bunsen while still managing debt, funding the pipeline, and supporting its dividend as it heads toward key loss of exclusivity dates.

But even with these positives, investors should be aware that the biggest issue remains how BMS eventually replaces expiring blockbuster revenue...

Bristol-Myers Squibb's narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This assumes revenue will decline by 6.2% per year and implies an earnings increase of about $1.3 billion from $7.3 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts paint a far harsher picture, assuming revenue could fall about 8 percent a year and earnings near US$8.1 billion by 2029, so if you are weighing this new AI news you may find that your own view on patent cliffs and pricing risk sits somewhere between these bearish assumptions and the more balanced consensus story.

Explore 8 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth as much as 85% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Find 50 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.